SCIENTECH (02291) plans to acquire a 54.2384% equity stake in Shanghai Minwei Biotechnology for 1.088 billion yuan.

SCIENTECH (02291) announced that on August 21, 2026, the company, the seller (LePu (Beijing) Medical Equipment Co., Ltd.), and Shanghai Minwei Biotechnology Co., Ltd. (the target company) entered into a share transfer agreement, whereby the company conditionally agreed to acquire and the seller conditionally agreed to sell a total of 54.2384% equity in the target company for a cash consideration of RMB 1.088 billion. The target company focuses on cardiovascular, endocrine, metabolic diseases, and their complications, possessing the GPCR agonist screening platform LAGMA, the RAF ultra-long-acting molecule development platform, and the Dual-siRNA development platform. It has the capability to screen for innovative drugs targeting multiple sites such as GLP-1/GIP, large molecular antibodies with longer half-lives and lower clinical dosages, and innovative siRNA drugs that can be administered at intervals of six months or even longer. As of the date of this announcement, the candidate drug MWX203 injection for dyslipidemia and candidate drug MWN105 injection for obesity are in Phase II clinical trials; candidate drug MWN109 tablets for obesity have completed Phase II clinical dosing; candidate drug MWN109 injection for obesity has entered Phase III clinical trials; candidate drug MWX401 injection for essential hypertension is undergoing Phase I clinical trials; and candidate drug MWN110 injection for weight control is in Phase I clinical trials.